MedTrace Logo

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

NCT06460987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 245

Last updated 2024-06-14

No results posted yet for this study

Summary

IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

Conditions

Interventions

DRUG

Finerenone

Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels

DRUG

RAS inhibitor

Receive RAS inhibitor treatment as specified in the KDIGO guidelines

DRUG

Immune Suppressant

Receive immune suppressant treatment as specified in the KDIGO guidelines

Sponsors & Collaborators

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    lead OTHER

Principal Investigators

  • Qiaorui Wang, bachelor · Student

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06460987 on ClinicalTrials.gov